Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability
Open Access
- 7 June 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 25 (11), 3707-3717
- https://doi.org/10.1093/ndt/gfq292
Abstract
Background. Phosphate binders are required to control serum phosphorus in dialysis patients. A phosphate binder combining calcium and magnesium offers an interesting therapeutic option. Methods. This controlled randomized, investigator-masked, multicentre trial investigated the effect of calcium acetate/magnesium carbonate (CaMg) on serum phosphorus levels compared with sevelamer hydrochloride (HCl). The study aim was to show non-inferiority of CaMg in lowering serum phosphorus levels into Kidney Disease Outcome Quality Initiative (K/DOQI) target level range after 24 weeks. Three hundred and twenty-six patients from five European countries were included. After a phosphate binder washout period, 255 patients were randomized in a 1:1 fashion. Two hundred and four patients completed the study per protocol (CaMg, N = 105; dropouts N = 18; sevelamer-HCl, N = 99; dropouts N = 34). Patient baseline characteristics were similar in both groups. Results. Serum phosphorus levels had decreased significantly with both drugs at week 25, and the study hypothesis of CaMg not being inferior to sevelamer-HCl was confirmed. The area under the curve for serum phosphorus (P = 0.0042) and the number of visits above K/DOQI (≤1.78 mmol/L, P = 0.0198) and Kidney disease: Improving global outcomes (KDIGO) targets (≤1.45 mmol/L, P = 0.0067) were significantly lower with CaMg. Ionized serum calcium did not differ between groups; total serum calcium increased in the CaMg group (treatment difference 0.0477 mmol/L; P = 0.0032) but was not associated with a higher risk of hypercalcaemia. An asymptomatic increase in serum magnesium occurred in CaMg-treated patients (treatment difference 0.2597 mmol/L, P < 0.0001). There was no difference in the number of patients with adverse events. Conclusion. CaMg was non-inferior to the comparator at controlling serum phosphorus levels at Week 25. There was no change in ionized calcium; there was minimal increase in total serum calcium and a small increase in serum magnesium. It had a good tolerability profile and thus may represent an effective treatment of hyperphosphataemia.This publication has 52 references indexed in Scilit:
- Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled TrialsAmerican Journal of Kidney Diseases, 2009
- Iron-Magnesium Hydroxycarbonate (Fermagate)Clinical Journal of the American Society of Nephrology, 2009
- Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney diseaseNephrology Dialysis Transplantation, 2008
- Disordered Mineral Metabolism in Hemodialysis Patients: An Analysis of Cumulative Effects in the Hemodialysis (HEMO) StudyAmerican Journal of Kidney Diseases, 2008
- Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2008
- Serum Phosphate Levels and Risk of Infection in Incident Dialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Association of Bone Activity, Calcium Load, Aortic Stiffness, and Calcifications in ESRDJournal of the American Society of Nephrology, 2008
- Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trialInternational Urology and Nephrology, 2008
- Magnesium Carbonate Is an Effective Phosphate Binder for Chronic Hemodialysis Patients: A Pilot StudyJournal of Renal Nutrition, 2007
- Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patientsClinical Nephrology, 2007